Annual report pursuant to Section 13 and 15(d)

Stockholders' Equity (Deficit) and Capitalization (Detail Textuals)

v3.20.1
Stockholders' Equity (Deficit) and Capitalization (Detail Textuals) - USD ($)
 1 Months Ended 12 Months Ended
Dec. 20, 2019
Nov. 30, 2019
Feb. 16, 2018
Jan. 19, 2018
Dec. 31, 2019
Dec. 31, 2018
Nov. 15, 2018
Equity [Line Items]              
Common stock, shares authorized         500,000,000 500,000,000 500,000,000
Common stock gross proceeds         $ 1,919,372 $ 3,095,908  
Warrant liability, issuance costs           137,192  
2018 Emerald Financing Warrants              
Equity [Line Items]              
Warrants exercise 40,800,000       40,800,000    
Intrinsic value of warrant exercises         $ 4,284,000    
Number of warrants issued         40,800,000    
Warrant exercise price         $ 0.10    
Series B Warrants              
Equity [Line Items]              
Intrinsic value of warrant exercises           $ 144,375  
Number of warrants issued           187,500  
Direct offering              
Equity [Line Items]              
Number of stock sold   8,000,000          
Common stock, par value (per share)   $ 0.001          
Net proceeds from the transaction   $ 1,919,372          
Number of warrants issued   8,000,000          
Private placement              
Equity [Line Items]              
Emerald financing issuance costs         $ 154,092    
Warrant liability, issuance costs         137,192    
Reduction to APIC from the issuance of common stock         $ 16,900    
Securities Purchase Agreement | Emerald Health Sciences Inc              
Equity [Line Items]              
Common stock issued     15,000,000 15,000,000      
Number of warrants issued     20,400,000 20,400,000      
Warrant exercise price     $ 0.10 $ 0.10      
Common stock gross proceeds       $ 1,500,000      
Subsequent financing purchase price, description       The Securities Purchase Agreement also provides that in the case of a subsequent financing in which the purchase price is less than $0.10 per share, Emerald Health Sciences shall be issued additional shares in order to protect against anti-dilution.      
Term of warrants     5 years        
Securities Purchase Agreement | Emerald Health Sciences Inc | Accredited Investor              
Equity [Line Items]              
Common stock issued     2,500,000        
Number of warrants issued     3,400,000        
Warrant exercise price     $ 0.10        
Common stock gross proceeds     $ 1,750,000        
Term of warrants     5 years